Community Events

Since it was founded in 2000, the TELUS Ride For Dad has donated more than $33 million to the Prostate Cancer Fight Foundation to fund research and awareness campaigns across Canada.

Your support is helping to make a difference in prostate cancer research, diagnosis and treatment! One of the main goals of the Prostate Cancer Fight Foundation and the TELUS Ride For Dad is to award research grants for new and innovative breakthrough science; research that can make a difference for persons diagnosed with prostate cancer.

Ride YearChapterProject TitleLead Researcher
2018YukonImproving Prostate Cancer Diagnosis and Management in the YukonJohn Lewis, University of Alberta
2018WindsorSuppression of prostate-specific membrane antigen (PSMA) in poor prognostic neuroendocrine prostate cancer differentiation, imaging and therapyDr. Lisa A. Porter, University of Windsor, Biological Sciences
2018Swift CurrentFactors affecting Prostate Cancer outcomes in SK: a comprehensive epidemiological reviewDr. Michael Szafron, School of Public Health, University of Saskatchewan
2018SaskatoonEradication of localized prostate cancer by irreversible electroporation ablation combined with immunotherapy via converting tolerogenic tumor microenvironment.Jim Xiang, M.D., Ph.D, Department of Oncology, College of Medecine, University of Saskatchewan
2018OttawaAnalysis of the innate lymphocyte landscape in prostate cancer.Michele Ardolino, Ottawa Hospital Research Institute/University of Ottawa
2018OttawaThe Role of Beta1 Integrin Signaling in promote bone metastatic prostate cancer growth.Christina Addison, Ottawa Hospital Research Institute
2018OkanaganHigh Dose Rate Brachytherapy for Prostate CancerDr. Juanita Crook, BC Cancer Foundation
2018NipissingFactors associated with prostate cancer stage at diagnosis, treatment and survival: the effects of geographic region and rurality.Dr. Michael Conlon PhD, Health Sciences North Research Institute, NorthEast Cancer Centre, Dr. Andrew Pearce MD, Health Sciences North Research Institute, NorthEast Cancer Centre & Dr. Ryan Carlson MD, Health Sciences North Research Institute, NorthEast Cancer Centre
2018NiagaraClinical and Dosimetric Effects of Peri-rectal Spacers on Erectile Function in Men Undergoing Image Guided Prostate RadiotherapyDr. Abhi Hallock MD FRCPC LLM, Walker Family Cancer Center, Niagara Health
2018MontrealGenerating a population-based recurrence risk map based on PSMA-PET imaging to guide radiotherapy.Dr. Cynthia Ménard, Centre de recherche du CHUM
2018MonctonProstate cancer liquid biopsy: Plasma and urine extracellular vesicles profiles for early detection and risk stratification.Rodney Ouellette, Atlantic Cancer Research Institute
2018ManitobaLamin A/C levels in circulating tumor cellsSabine Mai, University of Manitoba
2018ManitobaIdentification of clinically relevant lysosomotropic agents to treat aggressive prostate cancer.Dr. Spencer Gibson, CancerCare Manitoba
2018LondonPre-clinical optimization and assessment of a novel blood-based circulating tumor cell (CTC) assay to differentiate between indolent versus aggressive disease.Dr. Alison Allan, Cancer Research Laboratories Program, London Regional Cancer Program, London Health Sciences Centre; and Lawson Health Research Institute
2018Kingston-QuinteTesting novel IL-27-based therapies for prostate cancerKatrina Gee, Queen's University
2018HuroniaPilot Study of Focal Salvage HDR Brachytherapy After Local Recurrence from BrachytherapyDr. Hans Chung, Sunnybrook Odette Cancer Centre
2018HuroniaStereotactic Body Radiotherapy for Post-Prostatectomy Patients with Localized Prostate Cancer: A Phase I StudyChia-Lin Tseng, Sunnybrook Health Sciences Centre, University of Toronto
2018HuroniaHigh Dose Rate (HDR) Brachytherapy Boost and Stereotactic Body Radiation Therapy (SBRT) for Intermediate Risk Prostate Cancer: Phase II Clinical Trial.Yaser Hasan MD FRCPC, Sunnybrook Odette Cancer Centre, University of Toronto
2018HuroniaDevelopment of patient-derived prostate cancer cells for early prediction of therapy responseStanley Liu, MD, PhD, Sunnybrook-Odette Cancer Centre
2018Grand RiverExploring the impact of a smoking cessation program on Prostate Cancer Patients undergoing Radiation Therapy TreatmentDr. Ernest Osei, Medical Physics Department, Grand River Hospital
2018Grand RiverPEARL: PSMA PET/CT, Evaluating its Application in Real Life (extension)Dr. Joda Kuk, Grand River Regional Cancer Centre
2018EdmontonImproving the Management of Prostate Cancer using Advanced Biofluid DiagnosticsJohn Lewis, University of Alberta
2018Calgary/Rural ABProstate-derived fibroblast ‘bystander cells’, proteinase signalling and prostate cancer cell regulationDr. Morley D. Hollenberg, University of Calgary Cumming School of Medicine
2018Rural AB/CalgaryProstate-derived fibroblast ‘bystander cells’, proteinase signalling and prostate cancer cell regulationDr. Morley D. Hollenberg, University of Calgary Cumming School of Medicine
2018AvalonEngrailed 2 as biomarker and driver of prostate cancer metastasis.Jules JE Doré, Ph.D., Memorial University of Newfoundland, Faculty of Medicine
2018AvalonCharacterization of a novel Myc-Pygo2 ribonucleoprotein complex that drives prostate cancer cell proliferationKenneth R. Kao, Memorial University of Newfoundland
2017Big Rideau/Kingston-Quinte

Real time MRI fused to cone beam CT guided biopsies of the prostate: The safety and feasibility of a novel method of prostate biopsy.

Dr. Jason Izard, Department of Urology, Kingston General Hospital & Dr. Alexandre Menard, Department of Diagnostic Imaging, Kingston General Hospital

2017Kingston-Quinte/Big Rideau

Real time MRI fused to cone beam CT guided biopsies of the prostate: The safety and feasibility of a novel method of prostate biopsy.

Dr. Jason Izard, Department of Urology, Kingston General Hospital & Dr. Alexandre Menard, Department of Diagnostic Imaging, Kingston General Hospital

2017Huronia

Pilot Study of Focal Salvage HDR Brachytherapy After Local Recurrence from Brachytherapy

Dr. Hans Chung, Sunnybrook Odette Cancer Centre

2017Huronia

Immune response dynamics in Gleason 9-10 patients undergoing radiotherapy: A proof of principle study

Lucas C. Mendez MD, Odette Cancer Centre, Sunnybrook Health Sciences Centre & Stanley Liu MD, PhD, Odette Cancer Centre, Sunnybrook Health Sciences Centre

2017Western NL/Avalon

Analysis of the interaction between the MYC oncoprotein and Pygo2 chromatin effector in prostate cancer

Dr. Kenneth Kao, Memorial University of Newfoundland

2017Avalon/Western NL

Analysis of the interaction between the MYC oncoprotein and Pygo2 chromatin effector in prostate cancer

Dr. Kenneth Kao, Memorial University of Newfoundland

2017Grand River

The feasibility of using DNA enzyme functionalized liposomes to sensitize hypoxic prostate cancer for radiotherapy

Dr. Runqing Jiang, PhD, MCCPM, Grand River Regional Cancer Centre; University of Waterloo; University of Guelph

2017Grand River

Gold nanoparticles functionalized with plant-extract for targeted treatment of canine prostate cancer

Andre Fleck, MSc., MCCPM, Medical Physicist, Medical Physics Department, Grand River Cancer Centre

2017Golden Horseshoe

Characterizing the high-risk prostate cancer patient: evaluation of clinical, oncological, and functional outcomes following robot-assisted radical prostatectomy

Bobby Shayegan, M.D., St. Joseph's Healthcare Hamilton, St. Joseph's Healthcare Foundation, McMaster University

2017Western NL/Avalon

Engrailed 2 regulation of prostate cancer metastasis

Jules JE Doré, Ph.D., Memorial University of Newfoundland, Faculty of Medicine

2017Edmonton

Improving the management of prostate cancer using advanced biofluid diagnostics

John Lewis, University of Alberta

2017Durham

Automated and standardized quality planning for prostate cancer radiotherapy

Alejandro Berlin, MD, MSc, Radiation Medicine Program, Princess Margaret Cancer Centre & Thomas Purdie, PhD, Department of Radiation Oncology, University of Toronto

2017Calgary

Coagulation proteinases, proteinase-activated receptors and prostate cancer progression

Morley D. Hollenberg, University of Calgary Cumming School of Medicine

2017Avalon/Western NL

Engrailed 2 regulation of prostate cancer metastasis

Jules JE Doré, Ph.D., Memorial University of Newfoundland, Faculty of Medicine